The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
A Randomized Study of How Physicians Interpret Research Funding Disclosures
Open accessAbstract
BACKGROUND: The effects of clinical-trial funding on the interpretation of trial results are poorly understood. We examined how such support affects physicians' reactions to trials with a high, medium, or low level of methodologic rigor. METHODS: We presented 503 board-certified internists with abstracts that we designed describing clinical trials of three hypothetical drugs. The trials had high, medium, or low methodologic rigor, and each report included one of three support disclosures: funding from a pharmaceutical company, NIH funding, or none. For both factors studied (rigor and funding), one of the three possible variations was randomly selected for inclusion in the abstracts. Follow-up questions assessed the physicians' impressions of the trials' rigor, their confidence in the results, and their willingness to prescribe the drugs. RESULTS: The 269 respondents (53.5% response rate) perceived the level of study rigor accurately. Physicians reported that they would be less willing to prescribe drugs tested in low-rigor trials than those tested in medium-rigor trials (odds ratio, 0.64; 95% confidence interval [CI], 0.46 to 0.89; P=0.008) and would be more willing to prescribe drugs tested in high-rigor trials than those tested in medium-rigor trials (odds ratio, 3.07; 95% CI, 2.18 to 4.32; P<0.001). Disclosure of industry funding, as compared with no disclosure of funding, led physicians to downgrade the rigor of a trial (odds ratio, 0.63; 95% CI, 0.46 to 0.87; P=0.006), their confidence in the results (odds ratio, 0.71; 95% CI, 0.51 to 0.98; P=0.04), and their willingness to prescribe the hypothetical drugs (odds ratio, 0.68; 95% CI, 0.49 to 0.94; P=0.02). Physicians were half as willing to prescribe drugs studied in industry-funded trials as they were to prescribe drugs studied in NIH-funded trials (odds ratio, 0.52; 95% CI, 0.37 to 0.71; P<0.001). These effects were consistent across all levels of methodologic rigor. CONCLUSIONS: Physicians discriminate among trials of varying degrees of rigor, but industry sponsorship negatively influences their perception of methodologic quality and reduces their willingness to believe and act on trial findings, independently of the trial's quality. These effects may influence the translation of clinical research into practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The source of research funding can lead to bias or perceptions of bias in the design, conduct, or interpretation of research.121 122”
From Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomisation (STROBE-MR): explanation and elaboration. (2021) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationBombardier, C., Laine, L., Reicin, A. S., Shapiro, D., Burgos‐Vargas, R., Davis, B. R., Day, R. O., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,014
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citationNorderyd, O. M., Koch, G., Papias, A., Köhler, A. A., Helkimo, A. N., Brahm, C., Lindmark, U., Lindfors, N., Mattsson, A., Rolander, B., et al. (2015) · PubMed · Cited by 3,584
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Response rates to mail surveys published in medical journals
Asch, D. A., Jedrziewski, M. K., & Christakis, N. A. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00126-1 · Cited by 2,110
Flagged first, then by citations
Research works printed but not linked: 1
- Sage WM, 2007, Tex Law Rev, 85, 1413
Cited by
Sorted by citations
Items 101–183 of 183
Conflict of interest: a hazard for epidemiology
Acquavella, J. (2019) · Annals of Epidemiology · doi:10.1016/j.annepidem.2019.03.003 · Cited by 5
Improving Health With Partnerships Between Academia and Industry
Desmond-Hellmann, S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.826 · Cited by 5
Kong, N. H. Y., & Chow, P. K. H. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.03.012 · Cited by 4
The Influence of Disclosure and Ethics Education on Perceptions of Financial Conflicts of Interest
Sacco, D. F., Bruton, S. V., Alen Hajnal, A., & Lustgraaf, C. J. N. (2014) · Science and Engineering Ethics · doi:10.1007/s11948-014-9572-6 · Cited by 4
Leite, E. T. T., de Moraes, F. Y., Marta, G. N., Taunk, N. K., Vieira, M. T. L., Hanna, S. A., Silva, J. L. F. D., & de Carvalho, H. A. (2017) · The Breast · doi:10.1016/j.breast.2017.02.016 · Cited by 4
Rethinking the Use of Physicians as Hired Expert Lecturers
Avorn, J. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0847 · Cited by 3
Self-citationFinancial Conflicts of Interest, Disclosure, and Academic Discipline
Bruton, S. V., Sacco, D. F., & DIDLAKE, R. H. (2016) · Journal of Empirical Research on Human Research Ethics · doi:10.1177/1556264616636748 · Cited by 3
Confirmation Bias as a Factor in Pharmacy Student Assessment of Research Study Quality
Miller, D. R., & Jangula, S. J. (2018) · American Journal of Pharmaceutical Education · doi:10.5688/ajpe6754 · Cited by 4
Mooney, L. A., Fay, L., DeCastro, B., Zanki, T. A., & Mansi, B. A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1570770 · Cited by 4
Schroter, S., Pakpoor, J., Morris, J., Chew, M., & Godlee, F. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012677 · Cited by 3
Understanding the (perverse) effects of disclosing conflicts of interest: A direct replication study
Sah, S. (2018) · Journal of Economic Psychology · doi:10.1016/j.joep.2018.10.010 · Cited by 3
Villani, J., Ngo‐Metzger, Q., Vincent, I., & Klabunde, C. N. (2018) · JAMA · doi:10.1001/jama.2018.5404 · Cited by 3
The EHJ: the first years and the future
Lüscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu426 · Cited by 3
Reider, B. J. (2016) · The American Journal of Sports Medicine · doi:10.1177/0363546516639299 · Cited by 3
How Physicians Interpret Research Funding Disclosures
Feuerstein, J. D., Leffler, D. A., & Cheifetz, A. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1212744 · Cited by 3
What Does CME Accreditation Stand for?
Griebenow, R., Mills, P. G., & Stein, J. (2020) · Journal of European CME · doi:10.1080/21614083.2020.1822665 · Cited by 3
Fernández, J., Ribeiro, F. J., Dick, H. B., Kohnen, T., Rocha‐de‐Lossada, C., & Rodríguez‐Vallejo, M. (2025) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2025.07.016 · Cited by 2
Bartolo, C. A. D., & Braun, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-49547-7_2
Ethical and regulatory concerns of bioprinting
Wu, Y. B., Fuh, J. Y. H., & Ozbolat, I. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824291-9.00002-6 · Cited by 2
Global matters of epidemiology and the ethical challenges of addressing the health of populations
Salerno, J., Weed, D. L., Pandey, C. M., Crabb, V., Peters, E. S., & Hlaing, W. M. (2024) · Annals of Epidemiology · doi:10.1016/j.annepidem.2024.01.003 · Cited by 2
Hughes, E. A. G., Bakel, T. V., Raudanskis, A., Ray, P., Hodzic-Santor, B. H., Purohit, U., Sacks, C. A., & Fralick, M. (2024) · The Journal of Law Medicine & Ethics · doi:10.1017/jme.2024.135 · Cited by 2
Trust and transparency in clinical trials of medical devices
Kramer, D. B., & Cutlip, D. E. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.112 · Cited by 2
'Money Blinding' as a Solution to Biased Design and Conduct of Scientific Research
Robertson, C. T., & Rodwin, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802460-7.00008-5 · Cited by 2
Self-citationRafael Boscolo-berto, A., Montisci, M., Secco, S., D’Elia, C., Snenghi, R., Viel, G., & Ferrara, S. D. (2016) · Journal of Bioethical Inquiry · doi:10.1007/s11673-016-9732-2 · Cited by 2
Critical Evaluation of Nutrition Research
Brown, A. W., & Brown, M. M. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-43027-0_5 · Cited by 2
Keller, F., Marczewski, K., & Pavlović, D. (2016) · InTech eBooks · doi:10.5772/65104 · Cited by 2
Undergraduates' Perceptions of Conflict of Interest in Industry-Sponsored Research
Perry, H. B. (2018) · portal Libraries and the Academy · doi:10.1353/pla.2018.0008 · Cited by 2
Ethics and Industry Interactions
Kang, J. S. (2019) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2019.09.007 · Cited by 3
Analysis of Systematic Reviews in Clinical Practice Guidelines for Head and Neck Cancer
Dhillon, J., Khan, T., Siddiqui, B., Torgerson, T., Ottwell, R., Johnson, A., Skinner, M., Buchanan, P. C., Hartwell, M. L., & Vassar, M. B. (2022) · The Laryngoscope · doi:10.1002/lary.30051 · Cited by 2
Judge the science, not the funding source
Binks, M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.32 · Cited by 2
Physical education in Fiji and Solomon Islands: students' physical activity contexts
Dorovolomo, J. (2015) · Cross Connect (Southern Cross University) · Cited by 2
Funding for Biomedical Research
Sun, G. H., Steinberg, J. D., & Jagsi, R. (2013) · JAMA · doi:10.1001/jama.2013.1331 · Cited by 2
On the pitfalls of disclosure statements
Tseng, M., Hodge, A. M., Lachat, C. K., Vandevijvere, S., & Villamor, E. (2016) · Public Health Nutrition · doi:10.1017/s1368980016000070 · Cited by 1
Good Science for Good Pharma—A Public-Health Model
Light, D. W., & Maturo, A. F. (2015) · Palgrave Macmillan US eBooks · doi:10.1057/9781137374332_10 · Cited by 1
Understanding Conflict of Interest for Academic Entrepreneurs
Alapati, D., Egan, P., & Holcombe, J. (2019) · doi:10.21428/b2e239dc.2cbc8ecb · Cited by 1
Gajbhiye, S. V., Chindhalore, C. A., Gupta, A. K., & Dakhale, G. N. (2023) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2023.022 · Cited by 1
Aikin, K. J., O’Donoghue, A. C., Miles, S., DelGreco, M., & Burke, P. (2024) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2024.01.003 · Cited by 1
AlOtaiby, S., Otaiby, F. A., Almaghlouth, A., & AlNassar, S. (2024) · Cureus · doi:10.7759/cureus.59190 · Cited by 1
Securing the future: Financial ties of thoracic surgery program directors to industry
Nudotor, R. D., Ha, J. S., Ruck, J. M., Aziz, H., Kilic, A., & Bush, E. L. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.11.005 · Cited by 1
Griebenow, R., Schmidt, J., Herrmann, H., & Benson, S. (2025) · BMJ Open · doi:10.1136/bmjopen-2023-082907 · Cited by 1
Neilson, E., Villani, J., Mercer, S. L., Tilley, D. L., Vincent, I., Alston, A., & Klabunde, C. N. (2020) · Public Health Reports · doi:10.1177/0033354920954557 · Cited by 1
Berdahl, C. T., Addo, N., & Callaham, M. L. (2022) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12680 · Cited by 1
Essays in the Economics of Health Care and the Regulation of Medical Technology
Stern, A. D. (2014) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
The BMJ should not take the law into its own hands on competing interests
Forsyth, S. (2015) · BMJ · doi:10.1136/bmj.g7766 · Cited by 1
A Mathematical Approach to Comply with Ethical Constraints in Compassionate Use TreatmentsPreprint
Bruss, F. T. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1804.04628 · Cited by 1
Disclosing conflicts of interest has unintended effects
Reardon, S. (2014) · Nature · doi:10.1038/nature.2014.16077 · Cited by 1
Honesty and Truth in Academic Research and Writing
Lüscher, T. F. (2019) · Wiley eBooks · doi:10.1002/9781118907283.ch17 · Cited by 1
Addressing Conflict of Interest and Bias in Research, Education and Clinical Practice
Lau, D. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.06.002
NICOGOSSIAN, A. E., Kloiber, O., Doarn, C. R., Stabile, B. B., & Zimmerman, T. (2013) · World Medical & Health Policy · doi:10.1002/wmh3.71
Taylor, R. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-20264-8_5
Smith, G. P. (2014) · Australasian Psychiatry · doi:10.1177/1039856214529001
Yazıcı, Y. (2014) · Arthritis Care & Research · doi:10.1002/acr.22356
Surrogacy of Financial Conflicts of Interest
Meyer, R. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7933
Information transfer in medicine: modus vivendi out of paradise
Griebenow, R., Michalis, L. K., Schulenburg, D., Schaefer, R., & Weber, H. (2013) · Journal of European CME · doi:10.3402/jecme.v2i0.22598
Wolfla, C. E. (2013) · Neurosurgery · doi:10.1227/01.neu.0000430314.17068.79
The Pharmaceutical Market’s Adverse Effects
Kesselheim, A. S. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1288
Self-citationWhy Blinding? How Blinding? A Theory of Blinding and Its Application to Institutional Corruption
Robertson, C. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802460-7.00002-4
Self-citationSkopek, J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802460-7.00016-4
Relinquishment of Inappropriate Off-Label Uses: The Effect of the False Claims ActPreprint
Gentry, E. P. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.2911372
Piech, C. T., Lefèbvre, P., & Pike, C. T. (2017) · Springer eBooks · doi:10.1007/978-981-10-3262-2_5
A survey on information sources used by academic researchers to evaluate scientific instrumentsPreprint
Bergenholtz, C., MacAulay, S. C., Kolympiris, C., & Seim, I. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/253799
Transparency on scientific instruments
Bergenholtz, C., MacAulay, S. C., Kolympiris, C., & Seim, I. (2018) · EMBO Reports · doi:10.15252/embr.201845853
Protecting NIH’s Integrity and Trustworthiness in Public-Private Partnerships
Lo, B., & Grady, D. G. (2018) · JAMA · doi:10.1001/jama.2018.7625
The downsides of industry-funded development of new therapeutics
Adil, M. S., & Sultana, R. (2018) · Indian Journal of Health Sciences and Biomedical Research (KLEU) · doi:10.4103/kleuhsj.kleuhsj_164_17
Acquavella, J. (2019) · Annals of Epidemiology · doi:10.1016/j.annepidem.2019.06.006
Conflict Is in the Eye of the Beholder
Toledo, P., & Banayan, J. M. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005222
Information transfer in medicine: modus vivendi out of paradise*
Griebenow, R., Michalis, L., Schulenburg, D., Schaefer, R., & Weber, H. (2013) · Journal of European CME · doi:10.3109/21614083.2013.773906 · Cited by 1
Fleming, B. C. (2017) · The American Journal of Sports Medicine · doi:10.1177/0363546517716156
Bartolo, C. A. D., & Braun, M. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-49547-7_3
Liens d’intérêts et publications : bilan de 20 ans d’observations en médecine
Maisonneuve, H. (2022) · Colloque IRAFPA · doi:10.56240/cmb9911
Conflicts of Interest Between Neurologists and Pharmaceutical and Medical Device Industries
Robbins, N. M., & Smith, J. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-99680-2_48
Do Conflict of Interests Disclosures Work? Evidence from Citations in Medical JournalsPreprint
Leuz, C., Malani, A., Muhn, M., & Jakab, L. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4349559
Kovács, B. (2023) · doi:10.14267/phd.2023009
Les nouvelles frontières de l’intégrité académique
Maisonneuve, H. (2023) · EMS Editions eBooks · doi:10.3917/ems.berga.2023.01.0045
Sonar, S. S., Raderschadt, E., Gupta, S., Courtney, S., & Patel, R. J. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2527673
Coninck, D. D., Elewyck, P. V., Poels, K., & d’Haenens, L. (2025) · Communications · doi:10.1515/commun-2024-0159
Chansky, M. C., Price, S. M., Aikin, K. J., & O’Donoghue, A. C. (2022) · Figshare · doi:10.6084/m9.figshare.19619103
Chansky, M. C., Price, S. M., Aikin, K. J., & O’Donoghue, A. C. (2022) · Figshare · doi:10.6084/m9.figshare.19619106
From purity to proportionality: managing nonfinancial conflicts of interest in pain medicine
Webster, L. R. (2026) · Pain Medicine · doi:10.1093/pm/pnag018
Joffe, S., Bair, E. F., Gleason, K. A., Sellers, D. E., McGraw, S. A., Gross, C. P., Chen, D., Campbell, E. G., & Mello, M. M. (2026) · Clinical Trials · doi:10.1177/17407745261417337
Self-citationInstitutional Use of Meta-Research to Manage Conflict of Interest
Lozada-Martínez, I. D., Hernández-Páez, D. A., & Visconti-Lopez, F. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-27479-3_7
Loscertales, F. R. (2015) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Metadata
- Authors
- Kesselheim, A. S., Robertson, C. T., Myers, J. A., Rose, S. L., Gillet, V., Ross, K. M., Glynn, R. J., Joffe, S., & Avorn, J.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Cleveland Clinic (US)
- American Board of Internal Medicine (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-09-20
- Volume
- 367
- Issue
- 12
- Pages
- 1119-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3538846
- OpenAlex
- W2036907307
- Cited by
- 183
- References
- 54
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 9 · 2021: 5 · 2020: 5 · 2019: 13 · 2018: 26 · 2017: 13 · 2016: 23 · 2015: 15 · 2014: 28 · 2013: 22 · 2012: 3
- FWCI
- 24.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Harvard Catalyst
- ABIM Foundation
- Agency for Healthcare Research and Quality (K08HS018465, K08HS18465-01)
- National Cancer Institute (R25CA092203)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- clinical trial funding, research funding disclosure, pharmaceutical industry sponsorship, NIH funding, prescribing patterns, conflicts of interest, research integrity, generalizability of trial results, bias in clinical trials
- MeSH terms
- Data Collection, Drug Evaluation, Drug Industry, Humans, Internal Medicine, National Institutes of Health (U.S.), Physicians, Regression Analysis, Research Design, Research Support as Topic, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
